Jun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
May 27, 2020
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
May 26, 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
May 14, 2020
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
May 07, 2020
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
Apr 06, 2020
Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis
Feb 25, 2020
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
Feb 13, 2020
Promedior Announces Completion of Acquisition by Roche
Feb 06, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Dec 09, 2019
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting
Dec 07, 2019
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
Dec 02, 2019
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
Nov 20, 2019
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
Nov 15, 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
Nov 14, 2019
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
Nov 06, 2019
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Aug 16, 2019
FDA approves treatment for patients with rare bone marrow disorder
Jun 25, 2019
Global Myelofibrosis Market 2017-2018 & 2019-2026: Celgene's $1.1bn Impact Buy is First of More Deals to Come in 2018 and Beyond